Genetic Epidemiology of Ewing's Sarcoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,650
- 试验地点
- 1
- 主要终点
- Main effect of gene polymorphisms
研究概览
简要总结
This clinical trial studies genetic biomarkers from saliva samples in patients with Ewing sarcoma. Studying samples of saliva from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
详细描述
PRIMARY OBJECTIVES:
I. To determine the association between the length of Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 (EWS-FLI1) fusion protein binding sites (microsatellites) and risk of Ewing's sarcoma (ES).
II. To determine the frequency and commonality of Caucasian ancestral markers in cases of ES self-identified as non-Caucasian (African-American, Asian, Hispanic).
III. To determine the association between genomic variants in ES-related genes and hernia development (i.e. the integrin signaling pathway) and risk of ES.
OUTLINE:
研究设计
- 研究类型
- Observational
- 观察模型
- Family Based
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The patient is enrolled on ACCRN07
- •The patient has a diagnosis of Ewing Sarcoma (International Classification of Diseases [ICD] code morphology 9260; topography C40.0-C41.9, C76.0-C76.8, C80.9) and is registered with Children's Oncology Group (COG) by a North American member institution
- •The patient must be diagnosed with Ewing sarcoma between December 24, 2007 and December 31, 2015
- •The patient must have at least one biological parent alive and willing to participate
- •All questionnaire respondents must understand English or Spanish
- •Concomitant treatment on a therapeutic trial is not required
排除标准
- 未提供
结局指标
主要结局
Main effect of gene polymorphisms
时间窗: Up to 5 years
Risk ratios (RR) for the main effect of gene polymorphisms will be calculated using log-linear models. RRs and 95% confidence intervals for the gene-environment interaction are calculated by stratifying the likelihood according to case exposure.
次要结局
未报告次要终点